Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has issued an update.
Cambium Bio Limited has applied for quotation on the ASX of 4,363,637 new ordinary fully paid shares, to be traded under its existing ticker CMB. The new securities, issued on March 17, 2026, form part of a previously announced transaction and will increase the company’s free float, potentially enhancing liquidity for existing shareholders and supporting its capacity to raise capital in public markets.
The application under Appendix 2A confirms that these shares comply with ASX Listing Rules and formalises their admission to quotation. While the announcement does not disclose the underlying purpose of the issuance, the added stock on issue may signal ongoing corporate activity and could modestly dilute existing holdings while broadening the investor base.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited, listed on the ASX under the code CMB, operates in the life sciences sector, although the announcement provides no detail on its specific products or services. The company is headquartered in Australia and is subject to ASX Listing Rules in relation to the quotation and issuance of its securities.
Average Trading Volume: 11,160
Technical Sentiment Signal: Sell
Current Market Cap: A$11.02M
Find detailed analytics on CMB stock on TipRanks’ Stock Analysis page.